Pretnar-Oblak Janja, Sebestjen Miran, Sabovic Miso
Department of Neurology, Ljubljana Medical Center, Ljubljana, Slovenia.
Am J Hypertens. 2008 Jun;21(6):674-8. doi: 10.1038/ajh.2008.153. Epub 2008 May 1.
The pleiotropic effects of statins on the endothelial function are well recognized. However, the effect of statins might not be equally pronounced in the cerebral and systemic circulation. We compared cerebral and systemic endothelial function by L-arginine cerebrovascular reactivity and flow-mediated dilatation (FMD), respectively, in patients with arterial hypertension (AH) and healthy controls before and after atorvastatin treatment.
L-arginine reactivity and FMD were measured in patients with AH (29 patients, aged 61.1 +/- 6.2 years) and 21 healthy controls. The mean arterial velocity (v(m)) in both middle cerebral arteries was measured by transcranial Doppler sonography before, during, and after a 30-min intravenous infusion of L-arginine. FMD of the brachial artery after hyperemia was determined. The measurements were repeated after 3 months of treatment with atorvastatin.
L-arginine reactivity and FMD were decreased in patients with AH (12.5 +/- 8.7%; 2.7 +/- 5.0 %) compared with controls (21.3 +/- 10.9%; 8.5 +/- 5.9%) (P < 0.01). After atorvastatin treatment, L-arginine reactivity and FMD improved in patients with AH (19.5 +/- 10.6%; 4.6 +/- 4.1%) compared with the controls (20.2 +/- 10.2%; 9.7 +/- 3.9%). The use of statin restored the cerebral circulation reactivity, while there was little change in the systemic circulation measured by FMD.
The decreased L-arginine reactivity and FMD were found to improve after atorvastatin treatment in patients with AH, but the results suggest that statin therapy improved cerebral more than systemic endothelial function.
他汀类药物对内皮功能的多效性作用已得到充分认识。然而,他汀类药物的作用在脑循环和体循环中可能并不同样显著。我们分别通过L-精氨酸脑血管反应性和血流介导的血管舒张(FMD),比较了阿托伐他汀治疗前后高血压(AH)患者和健康对照者的脑内皮功能和体循环内皮功能。
对29例AH患者(年龄61.1±6.2岁)和21例健康对照者测量L-精氨酸反应性和FMD。在静脉输注L-精氨酸30分钟的前、中、后,通过经颅多普勒超声测量双侧大脑中动脉的平均动脉速度(v(m))。测定充血后肱动脉的FMD。阿托伐他汀治疗3个月后重复测量。
与对照组(21.3±10.9%;8.5±5.9%)相比,AH患者的L-精氨酸反应性和FMD降低(12.5±8.7%;2.7±5.0%)(P<0.01)。阿托伐他汀治疗后,与对照组(20.2±10.2%;9.7±3.9%)相比,AH患者的L-精氨酸反应性和FMD有所改善(19.5±10.6%;4.6±4.1%)。使用他汀类药物可恢复脑循环反应性,而通过FMD测量的体循环变化不大。
在AH患者中,阿托伐他汀治疗后L-精氨酸反应性和FMD降低的情况有所改善,但结果表明他汀类药物治疗对脑内皮功能的改善比对体循环内皮功能的改善更明显。